View the best moments of the 13th International Conference on Alzheimer’s & Parkinson’s Diseases. Mechanisms, Clinical Strategies, and Promising Treatments of Neurodegenerative Diseases
Held in the historic Austrian capital, the 13th AD/PD conference reflected a rapidly growing field. The meeting jammed science into five parallel sessions, with 545 talks running from early morning till late evening and some 1,200 posters vying for attention.
Read “Rates of Cortical Atrophy in Adults 80 Years and Older With Superior vs Average Episodic Memory”
Read the Alzheimer’s Forum analysis of the new AD-genetic risk score developed by Rahul Desikan (UCSF), Ole Andreassen (University of Oslo), Anders Dale (UCSD) and colleagues.
In lieu of a crystal ball that can foresee Alzheimer’s, scientists are trying to divine impending disease by looking deep into a person’s genome.
Read the exceptional compilation of AD-related data and statistics. Includes a Special Report on the Next Frontier of Alzheimer’s Research
Maria Carrillo, PhD, Chief Science Officer, Alzheimer’s Association discussing government, industry and the Alzheimer’s Association collaborations in larger scale trials and innovative projects.
As baby boomers age, an unprecedented number of people will be diagnosed with Alzheimer’s disease. The economic and social impacts will be wide reaching from cost of treatment to the effect on caregivers.
People spend about a third of their lives asleep. When we get too little shut-eye, it takes a toll on attention, learning and memory, not to mention our physical health. Virtually all animals with complex brains seem to have this same need for sleep. But exactly what is it about sleep that’s so essential?
Can exercise slow or prevent cognitive decline in older people at increased risk for Alzheimer’s disease?
The new NIA-supported EXERT study, in partnership with the YMCA, is looking to find the right dose of exercise to slow memory loss.
These concepts were approved at the National Advisory Council on Aging (NACA) meeting on January 18, 2017. We have posted the approved concepts here to give interested researchers maximal lead time to plan projects.
Only the Beginning: Read about a new milestone in AD research as the Brain Health Registry surpasses the 50,000 participant mark.
We are thrilled to begin the New Year with over 50,000 participants in Brain Health Registry! We are grateful for your help in achieving this significant milestone, and cannot thank you enough for your efforts to help scientists better understand brain disease.
Read a great synopsis of 2016 AD research developments in the Alzheimer’s Forum’s—A Year in Research by Tom Fagan and Gabrielle Strobel
No use soft-pedaling a hard truth: The year ended on a downer. Solanezumab—the therapeutic antibody in line to be the first approved AD drug in well over a decade—failed to significantly slow cognitive decline in people with mild AD and a positive amyloid scan/CSF Aβ profile.
Concerns over the Zika virus have focused on pregnant women due to mounting evidence that is causes brain abnormalities in developing fetuses. However, new research in mice suggests that certain adult brain cells may be vulnerable to infection as well.
The NIA’s Bypass Budget Proposal for Fiscal Year 2018—Stopping Alzheimer’s Disease and Related Dementias: Advancing Our Nation’s Research Agenda is now available
At the direction of Congress, the National Institutes of Health (NIH) develops an annual professional judgment budget to estimate the funds needed to fully pursue scientific opportunities to meet the research goal of the Plan—to effectively treat and prevent Alzheimer’s and related dementias by 2025.
Researchers presenting at the Alzheimer’s Association International Conference 2016 (AAIC 2016) in Toronto introduced and described a new condition or patient status, known as Mild Behavioral Impairment (MBI), that may be a forerunner of neurodegeneration and progression to mild cognitive impairment (MCI) or dementia.
Today the Senate Committee on Appropriations approved a bill that would boost U.S. government funding for Alzheimer’s disease to almost $1.4 billion in fiscal year 2017.
Science of Translational Medicine: New in vivo data published on beta amyloid as a protectant against pathogens
A protein called Aβ is thought to cause neuronal death in Alzheimer’s disease (AD). Aβ forms insoluble aggregates in the brains of patients with AD, which are a hallmark of the disease. Aβ and its propensity for aggregation are widely viewed as intrinsically abnormal. However, in new work, Kumar et al. show that Aβ is…
The UC Cures for Alzheimer’s Disease Initiative: A University of California-wide RFA now open for applications.
Sponsored by the UC Office of the President with a foundational grant of $4 million, the UC Cures initiative invited hundreds of laboratories throughout the 10-campus system to find new answers to Alzheimer’s disease and related disorders.
Nancy Reagan, former first lady and tireless Alzheimer’s caregiver and advocate for AD, passes at age 94
Nancy Reagan, the influential and stylish wife of the 40th president of the United States who unabashedly put Ronald Reagan at the center of her life but became a political figure in her own right, died on Sunday at her home in Los Angeles. She was 94.
Noted Canadian neurologist to head up UC San Diego’s Alzheimer’s Disease Cooperative Study. Howard Feldman of University of British Columbia is known for seminal research in dementias.
Howard Feldman of University of British Columbia is known for seminal research in dementias; UC launches new $4 million Alzheimer’s disease initiative.